MedTrace Logo

Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

NCT01073462 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2014-07-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to ascertain the percentage of cardiac patients with chronic kidney disease (CKD) stage 5 treated with paricalcitol IV achieving intact parathyroid hormone (iPTH) levels in target range of Kidney Disease Outcomes Quality Initiative (K/DOQI) treatment guidelines (150 - 300 pg/mL) after 2 years.

Conditions

  • Secondary Hyperparathyroidism
  • Chronic Kidney Disease Stage V
  • Cardiac Morbidity

Sponsors & Collaborators

  • Assign Data Management and Biostatistics GmbH

    collaborator OTHER

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Astrid Dworan-Timler · AbbVie Austria

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01073462 on ClinicalTrials.gov